JP2018531624A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531624A5
JP2018531624A5 JP2018531315A JP2018531315A JP2018531624A5 JP 2018531624 A5 JP2018531624 A5 JP 2018531624A5 JP 2018531315 A JP2018531315 A JP 2018531315A JP 2018531315 A JP2018531315 A JP 2018531315A JP 2018531624 A5 JP2018531624 A5 JP 2018531624A5
Authority
JP
Japan
Prior art keywords
seq
aav vector
subunit
promoter
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018531315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531624A (ja
JP6775584B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/050809 external-priority patent/WO2017044649A1/en
Publication of JP2018531624A publication Critical patent/JP2018531624A/ja
Publication of JP2018531624A5 publication Critical patent/JP2018531624A5/ja
Application granted granted Critical
Publication of JP6775584B2 publication Critical patent/JP6775584B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018531315A 2015-09-08 2016-09-08 設計されたメガヌクレアーゼを使用した網膜色素変性症の治療 Active JP6775584B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562215460P 2015-09-08 2015-09-08
US62/215,460 2015-09-08
PCT/US2016/050809 WO2017044649A1 (en) 2015-09-08 2016-09-08 Treatment of retinitis pigmentosa using engineered meganucleases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020168987A Division JP7068413B2 (ja) 2015-09-08 2020-10-06 設計されたメガヌクレアーゼを使用した網膜色素変性症の治療

Publications (3)

Publication Number Publication Date
JP2018531624A JP2018531624A (ja) 2018-11-01
JP2018531624A5 true JP2018531624A5 (enExample) 2020-10-01
JP6775584B2 JP6775584B2 (ja) 2020-10-28

Family

ID=57003577

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018531315A Active JP6775584B2 (ja) 2015-09-08 2016-09-08 設計されたメガヌクレアーゼを使用した網膜色素変性症の治療
JP2020168987A Active JP7068413B2 (ja) 2015-09-08 2020-10-06 設計されたメガヌクレアーゼを使用した網膜色素変性症の治療
JP2022074109A Pending JP2022110004A (ja) 2015-09-08 2022-04-28 設計されたメガヌクレアーゼを使用した網膜色素変性症の治療
JP2023182410A Pending JP2024023183A (ja) 2015-09-08 2023-10-24 設計されたメガヌクレアーゼを使用した網膜色素変性症の治療
JP2025079382A Pending JP2025131592A (ja) 2015-09-08 2025-05-12 設計されたメガヌクレアーゼを使用した網膜色素変性症の治療

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020168987A Active JP7068413B2 (ja) 2015-09-08 2020-10-06 設計されたメガヌクレアーゼを使用した網膜色素変性症の治療
JP2022074109A Pending JP2022110004A (ja) 2015-09-08 2022-04-28 設計されたメガヌクレアーゼを使用した網膜色素変性症の治療
JP2023182410A Pending JP2024023183A (ja) 2015-09-08 2023-10-24 設計されたメガヌクレアーゼを使用した網膜色素変性症の治療
JP2025079382A Pending JP2025131592A (ja) 2015-09-08 2025-05-12 設計されたメガヌクレアーゼを使用した網膜色素変性症の治療

Country Status (6)

Country Link
US (6) US10603363B2 (enExample)
EP (2) EP4530354A3 (enExample)
JP (5) JP6775584B2 (enExample)
AU (3) AU2016321244B2 (enExample)
CA (1) CA2997909A1 (enExample)
WO (1) WO2017044649A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015134812A1 (en) 2014-03-05 2015-09-11 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
EP3126495A1 (en) 2014-04-02 2017-02-08 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating primary open angle glaucoma
US11180793B2 (en) 2015-04-24 2021-11-23 Editas Medicine, Inc. Evaluation of Cas9 molecule/guide RNA molecule complexes
CA2997909A1 (en) * 2015-09-08 2017-03-16 Precision Biosciences, Inc. Treatment of retinitis pigmentosa using engineered meganucleases
KR20230170125A (ko) * 2017-04-21 2023-12-18 프리시젼 바이오사이언시스 인코포레이티드 Pcsk9 유전자 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
AU2018372763A1 (en) * 2017-11-21 2020-05-28 Bayer Healthcare Llc Materials and methods for treatment of autosomal dominant Retinitis Pigmentosa
CN120843482A (zh) 2019-05-07 2025-10-28 精密生物科学公司 用于识别序列的工程化大范围核酸酶的优化
WO2021113763A1 (en) * 2019-12-06 2021-06-10 Scribe Therapeutics Inc. Compositions and methods for the targeting of rhodopsin
WO2021212686A1 (zh) * 2020-04-21 2021-10-28 北京中因科技有限公司 RHO-adRP基于基因编辑的方法和组合物
US20230183664A1 (en) 2020-05-11 2023-06-15 Precision Biosciences, Inc. Self-limiting viral vectors encoding nucleases
WO2021231495A1 (en) * 2020-05-12 2021-11-18 Precision Biosciences, Inc. Treatment of retinitis pigmentosa using improved engineered meganucleases
US20250228973A1 (en) * 2021-10-19 2025-07-17 Precision Biosciences, Inc. Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
WO2025101946A1 (en) 2023-11-08 2025-05-15 Precision Biosciences, Inc. Polypeptide linkers for use in engineered meganucleases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
EP2628794B1 (en) 2005-10-18 2016-05-04 Precision Biosciences Rationally designed meganucleases with altered sequence specificity and DNA-binding affinity
WO2009059195A2 (en) 2007-10-31 2009-05-07 Precision Biosciences Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
EP2531609A1 (en) 2010-02-02 2012-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and therapy of retinitis pigmentosa
EP2569435A1 (en) 2010-05-12 2013-03-20 Cellectis Meganuclease variants cleaving a dna target sequence from the rhodopsin gene and uses thereof
US20120204282A1 (en) 2011-02-04 2012-08-09 Sangamo Biosciences, Inc. Methods and compositions for treating occular disorders
EP3683319A1 (en) 2011-06-01 2020-07-22 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
US20140287510A1 (en) 2011-11-08 2014-09-25 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute Rod cell-specific promoter
MX374529B (es) * 2013-12-12 2025-03-06 Broad Inst Inc Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para edicion del genoma.
ES3037550T3 (en) * 2014-03-12 2025-10-03 Prec Biosciences Inc Dystrophin gene exon deletion using engineered nucleases
CA2997909A1 (en) 2015-09-08 2017-03-16 Precision Biosciences, Inc. Treatment of retinitis pigmentosa using engineered meganucleases

Similar Documents

Publication Publication Date Title
JP2018531624A5 (enExample)
ZA202006432B (en) T cell receptors
MX389173B (es) Receptores de celulas t.
EA202091710A1 (ru) Антитела против cd73 и способы их применения
JP2015096070A5 (enExample)
EP4389898A3 (en) T cell receptors
JP2015212284A5 (enExample)
CL2019002280A1 (es) Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235)
UA124343C2 (uk) Капсиди аденоасоційованого вірусу і спосіб його використання
NZ731571A (en) T cell receptors
JP2017048194A5 (enExample)
EA201691111A1 (ru) Химерные белки фактора viii и их применение
FI3872085T3 (fi) Esimuotoiset virussekvenssit ja niiden käytöt
JP2017534262A5 (enExample)
WO2018022608A3 (en) Novel adeno-associated virus capsid proteins
EA201892250A1 (ru) Вакцина против rsv
JP2015533841A5 (enExample)
MX372992B (es) Vector de virus adeno-asociado.
JP2015524422A5 (enExample)
JP2017514522A5 (enExample)
JP2018528237A5 (enExample)
WO2016100328A8 (en) Novel tilapia virus and uses thereof
MX2024004293A (es) Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika.
JP2015524403A5 (enExample)
CN109937252A (zh) 重组dna聚合酶